Skip to main content

Advertisement

SpringerLink
Log in

Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objectives. Magnetic resonance spectroscopy (MRS) allows the contents of many metabolites in living tissues to be assessed. There is a good number of studies analyzing MRS data in Alzheimer’s disease (AD), though their results are contradictory. In this regard, there is value in comparing MRS data with fluorodeoxyglucose (FDG) positron emission tomography (PET) results, which assess the functional state of nervous tissue. The present study provides a comparison of MRI scan data in AD and moderate cognitive impairment (MCI) with the characteristics of cerebral glucose metabolism assessed from FDG-PET data. Materials and methods. Multivoxel proton MRS of the supraventricular region was carried out in patients with AD (n = 16) and MCI (n = 14). The following metabolite ratios were determined: NAA/Cr, Cho/Cr, and NAA/Cho (NAA is N-acetylaspartate, Cr is creatine, and Cho is choline). Patients underwent neurological investigation, assessment of cognitive status, and PET scans with FDG. Results. Patients with AD showed decreases in NAA/Cr and Cho/Cr in the white matter of the medial cortex of the supraventricular areas of both hemispheres. The MCI group showed a decrease in the NAA/Cr ratio in only one area of the white matter of the left hemisphere, adjacent to the parietal cortex. Positive correlations were found between NAA/Cr and Cho/Cr with measures of cognitive status and with the rate of glucose metabolism measured from PET data in the frontal, parietal, and temporal areas and the cingulate cortex. Conclusions. The decrease in the NAA/Cr ratio in the supraventricular white matter and the medial cortex in AD and the correlation of this parameter with cognitive test results and cerebral glucose metabolism constitute evidence that it may have diagnostic value, reflecting the severity of cognitive impairments. Assessment of the NAA/Cr ratio should be carried out with consideration of the fact that dementia alters the concentrations of both metabolites (NAA and Cr).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. M. Tabert, X. Liu, R. Doty, et al., “A 10-item smell identification scale related to risk for Alzheimer’s disease,” Ann. Neurol., 58, No. 1, 155–160 (2005).

    Article  Google Scholar 

  2. G. Verdile, S. Fuller, C. Atwood, et al., “The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught?” Pharmacol. Res., 50, 397–409 (2004).

    Article  CAS  Google Scholar 

  3. C. Mathis, N. Mason, B. Lopresti, and W. Klunk, “Development of positron emission tomography β-amyloid plaque imaging agents,” Semin. Nucl. Med., 42, No. 6, 423–432 (2012), https://doi.org/https://doi.org/10.1053/j.semnuclmed.2012.07.001.

    Article  Google Scholar 

  4. P. Trzepacz, P. Yu, J. Sun, K. Schuh, et al., Alzheimer’s Disease Neuroimaging Initiative, “Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia,” Neurobiol. Aging, 35, No. 1, 143–151 (2014), https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2013.06.018.

    Article  Google Scholar 

  5. M. Modo and J. Bulte (eds.), Magnetic Resonance Neuroimaging. Methods in Molecular Biology, Springer (2011), https://doi.org/https://doi.org/10.1007/978-1-61737-992-5_9.

    Google Scholar 

  6. P. B. Barker, A. Bizzi, N. De Stefano, et al., Clinical MR Spectroscopy: Techniques and Applications, Cambridge University Press (2009).

  7. K. K. Haga, Y. P. Khor, A. Farrall, and J. M. Wardlaw, “A systematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging,” Neurobiol. Aging, 30, 353–363 (2009), https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2007.07.005.

    Article  CAS  Google Scholar 

  8. C. Stagg and D. Rothman (eds.), Magnetic Resonance Spectroscopy. Tools for Neuroscience Research and Emerging Clinical Applications, Elsevier (2014).

  9. N. A. Semenova, T. A. Akhadov, A. V. Petryaikin, et al., “Metabolic impairments and the interaction of metabolic processes in the frontoparietal cortex of the brain in severe craniocerebral trauma. A study using local 1H magnetic resonance spectroscopy,” Biokhimiya, 77, No. 4, 493500 (2012).

  10. H. P. Hetherington, G. F. Mason, J. W. Pan, et al., “Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T,” Magn. Reson. Med., 32, No. 5, 565–571 (1994), https://doi.org/https://doi.org/10.1002/mrm.1910320504.

    Article  CAS  Google Scholar 

  11. A. Shiino, M. Matsuda, S. Morikawa, et al., “Proton magnetic resonance spectroscopy with dementia,” Surg. Neurol., 39, No. 2, 143–147 (1993), https://doi.org/https://doi.org/10.1016/0090-3019(93)90093-g.

    Article  CAS  Google Scholar 

  12. K. Kantarci, R. C. Petersen, and B. F. Boeve, “1H-MR spectroscopy in common dementias,” Neurology, 63, No. 8, 1393–1398 (2004), https://doi.org/https://doi.org/10.1212/01.wnl.0000141849.21256.ac.

    Article  CAS  Google Scholar 

  13. H. Wang, L. Tan, H. F. Wang, et al., “Magnetic resonance spectroscopy in Alzheimer’s disease: systematic review and meta-analysis,” J. Alzheimers Dis., 46, No. 4, 1049–1070 (2015), https://doi.org/https://doi.org/10.3233/JAD-143225.

    Article  CAS  Google Scholar 

  14. B. B. Frederick, A. Satlin, D. A. Yurgelun-Todd, and P. F. Renshaw, “In vivo proton magnetic resonance spectroscopy of Alzheimer’s disease in the parietal and temporal lobes,” Biol. Psychiatry, 42, No. 2, 147–150 (1997), https://doi.org/https://doi.org/10.1016/s0006-3223(97)00242-4.

    Article  Google Scholar 

  15. A. Bitsch, H. Bruhn, V. Vougioukas, et al., “Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy,” AJNR Am. J. Neuroradiol., 20, No. 9, 1619–1627 (1999).

    CAS  PubMed  Google Scholar 

  16. F. Jessen, W. Block, and F. Traber, “Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD,” Neurology, 55, No. 5, 684–688 (2000), www. ajnr.org/content/20/9/1619, acc. May 15, 2018.

    Article  CAS  Google Scholar 

  17. W. Huang, G. E. Alexander, L. Chang, et al., “Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1)H MRS study,” Neurology, 57, No. 4, 626–632 (2001), https://doi. org/https://doi.org/10.1212/wnl.57.4.626.

    Article  CAS  Google Scholar 

  18. A. Pfefferbaum, E. Adalsteinsson, D. Spielman, et al., “In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging,” Magn. Reson. Med., 41, No. 2, 276–284 (1999), https://doi. org/10.1002/(sici)1522-2594(199902)41:2<276::aid-mrm10>3.3.co.

  19. K. R. Krishnan, H. C. Charles, P. M. Doraiswamy, et al., “Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease,” Am. J. Psychiatry, 160, No. 11, 2003–2011 (2003), https://doi.org/https://doi.org/10.1176/appi.ajp.160.11.2003.

    Article  Google Scholar 

  20. S. Chantal, M. Labelle, R. W. Bouchard, et al., “Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease,” Arch. Neurol., 59, No.6, 955962 (2002), https://doi.org/https://doi.org/10.1001/archneur.59.6.955.

    Article  Google Scholar 

  21. S. Tumati, S. Martens, and A. Aleman, “Magnetic resonance spectroscopy in mild cognitive impairment: systematic review and meta-analysis,” Neurosci. Biobehav. Rev., 37, No. 10, Pt 2, 2571–2586 (2013), https://doi.org/https://doi.org/10.1016/j.neubiorev.2013.08.004.

    Article  Google Scholar 

  22. B. Zhang, T. J. Ferman, B. F. Boeve, et al., “MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer’s disease,” J. Neuroimaging, 25, No. 2, 269–274 (2015), https://doi.org/https://doi.org/10.1111/jon.12138.

    Article  CAS  Google Scholar 

  23. K. Kantarci, D. S. Knopman, D. W. Dickson, et al., “Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements,” Radiology, 248, No. 1, 210–220 (2008), https://doi.org/https://doi.org/10.1148/radiol.2481071590.

    Article  Google Scholar 

  24. A. M. N. Coutinho, F. H. G. Porto, P. F. Zampieri, et al., “Analysis of the posterior cingulate cortex with [18F]FDG-PET and Naa/mI in mild cognitive impairment and Alzheimer’s disease: Correlations and differences between the two methods,” Dement. Neuropsychol., 9, No. 4, 385–393 (2015), https://doi.org/https://doi.org/10.1590/1980-57642015DN94000385.

    Article  Google Scholar 

  25. S. V. Medvedev, T. Yu. Skvortsova, and R. N. Krasikova, PET in Russia: Positron Emission Tomography in the Clinic and Physiology, St. Petersburg (2008).

  26. A. A. Bogdan, Yu. G. Khomenko, G. V. Kataeva, and T. N. Trofimova, “Principles of data grouping in assessment of the results of multivoxel spectroscopic investigations of the brain,” Luch. Diagnost. Ter., 4, No. 7, 15–19 (2016).

    Google Scholar 

  27. R. A. Charlton, D. J. McIntyre, F. A. Howe, et al., “The relationship between white matter brain metabolites and cognition in normal aging: The GENIE study,” Brain Res., 1164, 108–116 (2007), https:// doi.org/https://doi.org/10.1016/j.brainres.2007.06.027.

    Article  CAS  Google Scholar 

  28. J. M. Allman, N. A. Tetreault, A. Y. Hakeem, et al., “The von Economo neurons in frontoinsular and anterior cingulate cortex,” Ann. N. Y. Acad. Sci., 1225, 59–71 (2011), https://doi.org/https://doi.org/10.1111/j.1749-6632.2011.06011.x.

  29. J. Talairach and P. Tournoux, Co-Planar Stereotactic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging, Thieme, New York (1988).

    Google Scholar 

  30. Statistical Parametric Mapping, www.fi l.ion.ucl.ac.uk/spm/, acc. May 15, 2018.

  31. WFU PickAtlas, www.nitrc.org/projects/wfu_pickatlas/, acc. May 15, 2018.

  32. I. Yakushev, C. Landvogt, H. G. Buchholz, et al., “Choice of reference area in studies of Alzheimer’s disease using positron emission tomography with fluorodeoxyglucose-F18,” Psychiatry Res., 164, No. 2, 143–153 (2008), http://dx.doi.org/https://doi.org/10.1016/j.pscychresns.2007.11.004.

    Article  Google Scholar 

  33. Yu. G. Khomenko, A. A. Bogdan, G. V. Kataeva, and E. M. Chernysheva, “Use of multivoxel magnetic resonance spectroscopy in investigations of patients with cognitive disorders,” Vestn. Stankt- Peterburg. Univ. Ser. 4, Fiz, Khim., 3, No. 1, 82–89 (2016).

    Google Scholar 

  34. N. Schuff, D. L. Amend, D. J. Meyerhoff, et al., “Alzheimer disease: Quantitative H-1 MR spectroscopic imaging of frontoparietal brain,” Radiology, 207, No. 1, 91–102 (1998).

    Article  CAS  Google Scholar 

  35. E. A. Gromova, A. A. Bogdan, G. V. Kataeva, et al., “Characteristics of the functional state of brain structures in HIV-infected patients,” Luch. Diagnost., 1, 41–48 (2016).

    Google Scholar 

  36. K. Weissenborn, B. Ahl, D. Fischer-Wasels, et al., “Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy,” Gut, 56, No. 12, 1736–1742 (2007), http:// dx.doi.org/https://doi.org/10.1136/gut.2006.110569.

    Article  Google Scholar 

  37. R. Mielke, H. H. Schopphoff, H. Kugel, et al., “Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer’s disease,” Int. J. Neurosci., 107, No. 34, 233–245 2001), https://doi.org/https://doi.org/10.3109/00207450109150687.

    Article  CAS  Google Scholar 

  38. J. O’Neill, J. L. Eberling, N. Schuff, et al., “Method to correlate 1H MRSI and 18FDG-PET,” Magn. Reson. Med., 43, No. 2, 244–50 (2000), https://doi.org/10.1002/(sici)1522-2594(200002)43:2<244:: aid-mrm11>3.3.co.

Download references

Author information

Authors and Affiliations

  1. Bekhtereva Institute of the Human Brain, Russian Academy of Sciences, St. Petersburg, Russia

    Yu. G. Khomenko, G. V. Kataeva, A. A. Bogdan, E. M. Chernysheva & D. S. Susin

Authors
  1. Yu. G. Khomenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. V. Kataeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Bogdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. M. Chernysheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. S. Susin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu. G. Khomenko.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 119, No. 1, Iss. 1, pp. 51–58, January, 2019.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khomenko, Y.G., Kataeva, G.V., Bogdan, A.A. et al. Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study. Neurosci Behav Physi 49, 1199–1207 (2019). https://doi.org/10.1007/s11055-019-00858-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-019-00858-1

Keywords

Search

Navigation